ABACAVIR
India: Patent on Salt
Case Status: Filed July 2006. Withdrawal of patent application within a year of opposition submitted, originator price reduced by 31%, generics were able to compete and prices come down over time to 77% of the original originator price.
LOPINAVIR/RITONAVIR
European Patent Office: Heat Stable Formation
Case Status: Filed in 2012.
European Patent Office: Heat Stable Formation
Case Type: Pre-grant observation filed by other parties
Case Status: Filed in 2007. Patent granted in 2008. While we lost this case, generics and multinationals subsequently contested the patent because the evidence I-MAK raised in its challenge paved the way.
India: Polymorph
Case Status: Filed in 2006. The patent application was rejected in 2010.
India: Polymorph
Case Status: Filed in 2006. The patent application was rejected in 2011.
India: Heat Stable Tablet Formulation
Case Status: Filed in August 2007. The patent application was rejected in 2011.
India: Soft-gel Capsule Formulation
Case Status: Filed in 2006. Abbvie abandoned the patent application within a few months.
NEVIRAPINE
India: Syrup Formulation
Case Status: Filed in 2006. Patent was rejected in June 2008.
TENOFOVIR
India: Prodrug
Case Status: Filed in 2006. Gilead offered a license to produce it at lowest cost within months of filing; patent application was rejected in September 2009.
India: Salt Compound for Formulation
Case Status: Filed in 2006. Gilead offered a license to produce it at lowest cost within months of filing; patent application was rejected in September 2009.